The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 401–500 of 1,000
Wang, M., Hou, Z., Liu, S., Liang, S., Ding, B., Zhao, Y., Chang, M., Han, G., Kheraif, A. A. A., & Lin, J. (2021) · Small · doi:10.1002/smll.202005728 · Cited by 113
Krisnawan, V. E., Stanley, J. A., Schwarz, J. K., & DeNardo, D. G. (2020) · Cancers · doi:10.3390/cancers12102916 · Cited by 115
Lee, B. Y., Hogg, E. K. J., Below, C., Kononov, A., Blanco‐Gómez, A., Heider, F., Xu, J., Hutton, C., Zhang, X. M., Scheidt, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27607-8 · Cited by 115
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
Kunk, P. R., Bauer, T. W., Slingluff, C. L., & Rahma, O. E. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0119-z · Cited by 110
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Puré, E., & Lo, A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0011 · Cited by 112
Fabre, M., Ferrer, C., Domínguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2238 · Cited by 124
Determinants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, R., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 119
Zhu, L., Liu, J., Zhou, G., Liu, T., Dai, Y., Nie, G., & Zhao, Q. (2021) · Small · doi:10.1002/smll.202102624 · Cited by 109
Self-citationHeiser, C. N., Simmons, A. J., Revetta, F. L., McKinley, E. T., Ramirez-Solano, M. A., Wang, J., Kaur, H., Shao, J., Ayers, G. D., Wang, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.006 · Cited by 112
Research trends in pharmacological modulation of tumor‐associated macrophages
Wang, N., Wang, S., Wang, X., Zheng, Y., Yang, B., Zhang, J., Pan, B., Gao, J., & Wang, Z. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.288 · Cited by 111
Zhu, Y., Li, X., Wang, L., Hong, X., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.988295 · Cited by 116
Feng, Y., Ma, W., Zang, Y., Guo, Y., Li, Y., Zhang, Y., Dong, X., Liu, Y., Zhan, X., Pan, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54710-3 · Cited by 128
Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
Wang, S., Li, Y., Cheng, X., Ding, C., Zhang, H., Chen, L., You, L., Dai, M., & Zhao, Y. (2020) · PubMed Central · Cited by 107
Liu, X., Tang, R., Xu, J., Tan, Z., Liang, C., Meng, Q., Lei, Y., Hua, J., Zhang, Y., Liu, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-329349 · Cited by 108
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 116
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
Hartupee, C. D., Nagalo, B. M., Chabu, C. Y., Tesfay, M. Z., Coleman‐Barnett, J., West, J. T., & Moaven, O. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1287459 · Cited by 116
D’Alterio, C., Buoncervello, M., Ieranò, C., Napolitano, M., Portella, L., Rea, G., Barbieri, A., Luciano, A., Scognamiglio, G., Tatangelo, F., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1420-8 · Cited by 114
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 111
Akiyama, T., Yasuda, T., Uchihara, T., Yasuda‐Yoshihara, N., Tan, B. J. Y., Yonemura, A., Semba, T., Yamasaki, J., Komohara, Y., Ohnishi, K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1890 · Cited by 107
Sun, R., Sun, Y., Wu, C., Liu, Y., Zhou, M., Yiwei, D., Du, G., Luo, H., Shi, B., Jiang, H., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.010 · Cited by 115
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 108
Jia, C., Wang, G., Wang, T., Fu, B., Zhang, Y., Huang, L., Deng, Y., Chen, G., Wu, X., Chen, J., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45446 · Cited by 108
Fibroblasts in pancreatic cancer: molecular and clinical perspectives
Rebelo, R., Xavier, C. P. R., Giovannetti, E., & Vasconcelos, M. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.03.002 · Cited by 109
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02900-0 · Cited by 106
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F. M., & Beatty, G. L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2053-4 · Cited by 105
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Şahin, İ. H., Askan, G., Hu, Z., & O'Reilly, E. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx503 · Cited by 108
Kashima, H., Noma, K., Ohara, T., Kato, T., Katsura, Y., Komoto, S., Sato, H., Katsube, R., Ninomiya, T., Tazawa, H., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31953 · Cited by 105
Targeting the Microenvironment in Advanced Colorectal Cancer
Tauriello, D. V. F., & Batlle, E. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.001 · Cited by 106
Sethi, V., Vitiello, G. A., Saxena, D. B., Miller, G., & Dudeja, V. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.045 · Cited by 104
Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma
Sperb, N., Tsesmelis, M., & Wirth, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155486 · Cited by 109
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 102
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Javed, S. A., Najmi, A., Ahsan, W., & Zoghebi, K. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383456 · Cited by 111
Stellate Cells in Tissue Repair, Inflammation, and Cancer
Sherman, M. H. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062855 · Cited by 104
Freeman, P., & Mielgo, A. (2020) · Cancers · doi:10.3390/cancers12092687 · Cited by 106
Simon, T., & Salhia, B. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0282 · Cited by 103
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Liu, L., Huang, X., Shi, F., Song, J., Guo, C., Yang, J., Liang, T., & Bai, X. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02273-w · Cited by 105
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Bärthel, S., Falcomatà, C., Rad, R., Theis, F. J., & Saur, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00526-x · Cited by 105
Stenmark, K. R., Tuder, R. M., & Kasmi, K. C. E. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00283.2015 · Cited by 103
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 105
T cells in pancreatic cancer stroma
Goulart, M. R., Stasinos, K., Fincham, R. E. A., Delvecchio, F. R., & Kocher, H. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i46.7956 · Cited by 100
Poschke, I. C., Faryna, M., Bergmann, F., Floßdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T. P., Ehrenberg, R., Volkmar, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240859 · Cited by 101
Ansems, M., & Span, P. N. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.001 · Cited by 103
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107
Luheshi, N., Ulrichsen, J. C., Harper, J. A., Mullins, S., Sulikowski, M., Martin, P., Brown, L., Lewis, A. R., Davies, G. C., Morrow, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7610 · Cited by 100
Hepatic stellate cells secreting WFA + ‐M2BP: Its role in biological interactions with Kupffer cells
Bekki, Y., Yoshizumi, T., Shimoda, S., Itoh, S., Harimoto, N., Ikegami, T., Kuno, A., Narimatsu, H., Shirabe, K., & Maehara, Y. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13708 · Cited by 99
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Zhang, E., Gu, J., & Xu, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0759-3 · Cited by 103
Pancreatic cancer microenvironment: a current dilemma
Uzunparmak, B., & Şahin, İ. H. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0221-1 · Cited by 95
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 100
Ogawa, Y., Masugi, Y., Abe, T., Yamazaki, K., Ueno, A., Fujii‐Nishimura, Y., Hori, S., Yagi, H., Yuta, A., Kitago, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2298 · Cited by 99
Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 113
Levesque, C., & Nelson, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030510 · Cited by 101
Cytotoxic T cells swarm by homotypic chemokine signalling
Niño, J. L. G., Pageon, S. V., Tay, S. S., Colakoglu, F., Kempe, D., Hywood, J. D., Mazalo, J. K., Cremasco, J., Govendir, M., Dagley, L. F., et al. (2020) · eLife · doi:10.7554/elife.56554 · Cited by 98
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
Peltier, A., Seban, R., Buvat, I., Bidard, F., & Mechta‐Grigoriou, F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.008 · Cited by 96
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
Liu, H., Zhao, H., & Sun, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.004 · Cited by 100
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 102
TGF-β Mediated Immune Evasion in Cancer—Spotlight on Cancer-Associated Fibroblasts
Ghahremanifard, P., Chanda, A., Bonni, S., & Bose, P. (2020) · Cancers · doi:10.3390/cancers12123650 · Cited by 99
Hao, X., Ren, Y., Feng, M., Wang, Q., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111798 · Cited by 101
Vaish, U., Jain, T., Are, A. C., & Dudeja, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413408 · Cited by 102
Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment
Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I. (2022) · Cancers · doi:10.3390/cancers14143321 · Cited by 107
Kim, D. K., Jeong, J., Lee, D. S., Hyeon, D. Y., Park, G. W., Jeon, S., Lee, K. B., Jang, J., Hwang, D., Kim, H. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33991-6 · Cited by 102
IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma
Pandey, S., Mourcin, F., Marchand, T., Nayar, S., Guirriec, M., Pangault, C., Monvoisin, C., Amé-Thomas, P., Guilloton, F., Dulong, J., et al. (2017) · Blood · doi:10.1182/blood-2016-08-737239 · Cited by 101
Determinants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 96
Bockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
The role of the tumour microenvironment in immunotherapy
Gasser, S., Lim, L. H. K., & Cheung, F. S. G. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0146 · Cited by 90
Kather, J. N., & Halama, N. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0441-6 · Cited by 95
Smit, M. J., Schlecht‐Louf, G., Neves, M., van den Bor, J., Penela, P., Siderius, M. H., Bachelerie, F., & Mayor, F. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023340 · Cited by 92
Wen, X., He, X., Jiao, F., Wang, C., Sun, Y., Ren, X., & Li, Q. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14768383625385 · Cited by 96
Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 91
Pu, N., Gao, S., Yin, H., Li, J.-A., Wu, W., Fang, Y., Zhang, L., Rong, Y., Xu, X., Wang, D., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.013 · Cited by 91
Diana, A., Wang, L. M., D’Costa, Z., Allen, P., Azad, A., Silva, M. A., Soonawalla, Z. F., Liu, S. K., McKenna, W. G., Muschel, R. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10038 · Cited by 89
Gene-expression profiling to predict responsiveness to immunotherapy
Jamieson, N. B., & Maker, A. V. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.63 · Cited by 90
Involvement of local renin‐angiotensin system in immunosuppression of tumor microenvironment
Nakamura, K., Yaguchi, T., Ohmura, G., Kobayashi, A., Kawamura, N., Iwata, T., Kiniwa, Y., Okuyama, R., & Kawakami, Y. (2017) · Cancer Science · doi:10.1111/cas.13423 · Cited by 94
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R. O., Palucka, K., Samayoa, J. A., Spranger, S., Warren, S. E., Wong, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 90
He, C., Huang, X., Zhang, Y. L., Lin, X., & Li, S. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.39 · Cited by 93
Jo, S. D., Nam, G., Kwak, G., Yang, Y., & Kwon, I. C. (2017) · Nano Today · doi:10.1016/j.nantod.2017.10.008 · Cited by 89
Guo, J. X., Zeng, H., & Chen, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00014 · Cited by 91
Cellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 97
Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer
Choi, Y. W., Kim, Y. H., Oh, S. Y., Suh, K. W., Kim, Y., Lee, G., Yoon, J. E., Park, S. S., Lee, Y., Park, Y. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202002497 · Cited by 92
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
Park, K., Veena, M. S., & Shin, D. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830208 · Cited by 91
Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
Zhang, A. Q., Hostetler, A., Chen, L. E., Mukkamala, V., Abraham, W. D., Padilla, L. T., Wolff, A. N., Maiorino, L., Backlund, C. M., Aung, A., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01048-8 · Cited by 93
Demir, I., Kujundzic, K., Pfitzinger, P., Saricaoglu, Ö. C., Teller, S., Kehl, T., Reyes, C. M., Ertl, L., Miao, Z., Schall, T., et al. (2016) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1606909114 · Cited by 82
Cioffi, M., Trabulo, S. M. D., Vallespinós, M., Raj, D., Kheir, T. B., Lin, M.-L., Begum, J., Baker, A., Amgheib, A., Saif, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15450 · Cited by 88
Wang, Y., Gao, Z., Du, X., Chen, S., Zhang, W., Wang, J., Li, H., He, X., Cao, J., & Wang, J. (2020) · Biomaterials Science · doi:10.1039/d0bm00916d · Cited by 88
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters
Wang, S., Xie, K., & Liu, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690112 · Cited by 90
Manoukian, P., Bijlsma, M. F., & van Laarhoven, H. W. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743907 · Cited by 95
Opzoomer, J. W., Anstee, J. E., Dean, I., Hill, E. J., Bouybayoune, I., Caron, J., Muliaditan, T., Gordon, P., Sosnowska, D., Nuamah, R. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg9518 · Cited by 94
Kras and tumor immunity: friend or foe?
Cullis, J., Das, S., & Bar-Sagi, D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031849 · Cited by 85
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 87
Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment
Lin, Y., Li, B., Yang, X., Cai, Q., Liu, W., Tian, M., Luo, H., Yin, W., Song, Y. Y., Shi, Y., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.10.005 · Cited by 90
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 89
Functional diversity of cancer‐associated fibroblasts in modulating drug resistance
Bu, L., Baba, H., Yasuda, T., Uchihara, T., & Ishimoto, T. (2020) · Cancer Science · doi:10.1111/cas.14578 · Cited by 85
TGFβ Signaling in the Pancreatic Tumor Microenvironment
Principe, D. R., Timbers, K. E., Atia, L. G., Koch, R. M., & Rana, A. (2021) · Cancers · doi:10.3390/cancers13205086 · Cited by 85
LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling
Yang, J., Liu, F., Wang, Y., Qu, L., & Lin, A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215798 · Cited by 85
Obesity and prostate cancer — microenvironmental roles of adipose tissue
Saha, A., Kolonin, M. G., & DiGiovanni, J. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00764-9 · Cited by 88
Gautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 93
T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution
Yang, W., Liu, S., Mao, M., Gong, Y., Li, X., Lei, T., Liu, C., Wu, S., & Hu, Q. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02960-w · Cited by 95
Krueger, T. E. G., Thorek, D. L. J., Meeker, A. K., Isaacs, J. T., & Brennen, W. N. (2018) · The Prostate · doi:10.1002/pros.23738 · Cited by 90
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 87
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
